quinidine has been researched along with Pituitary Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashton, C; Carmichael, JD; Rhie, SK; Zada, G | 1 |
| Greer, MA; Greer, SE; McAdams, S; Sato, N; Wang, XB | 1 |
2 other study(ies) available for quinidine and Pituitary Neoplasms
| Article | Year |
|---|---|
Role of KCNAB2 expression in modulating hormone secretion in somatotroph pituitary adenoma.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Growth Hormone-Secreting Pituitary Adenoma; Hormone Antagonists; Human Growth Hormone; Humans; Pituitary Hormones; Pituitary Neoplasms; Prolactin; Quinidine; Rats; RNA, Small Interfering; Shaker Superfamily of Potassium Channels | 2020 |
Quinidine inhibits prolactin secretion induced by thyrotropin-releasing hormone, high medium potassium or hyposmolarity in GH4C1 cells.
Topics: Anti-Arrhythmia Agents; Humans; Osmolar Concentration; Pituitary Neoplasms; Potassium; Prolactin; Quinidine; Tetradecanoylphorbol Acetate; Thyrotropin; Thyrotropin-Releasing Hormone; Time Factors; Tumor Cells, Cultured | 1991 |